Gene dosage compensation: Origins, criteria to identify compensated genes, and mechanisms including sensor loops as an emerging systems-level property in cancer
- PMID: 37987212
- PMCID: PMC10757140
- DOI: 10.1002/cam4.6719
Gene dosage compensation: Origins, criteria to identify compensated genes, and mechanisms including sensor loops as an emerging systems-level property in cancer
Abstract
The gene dosage compensation hypothesis presents a mechanism through which the expression of certain genes is modulated to compensate for differences in the dose of genes when additional chromosomes are present. It is one of the means through which cancer cells actively cope with the potential damaging effects of aneuploidy, a hallmark of most cancers. Dosage compensation arises through several processes, including downregulation or overexpression of specific genes and the relocation of dosage-sensitive genes. In cancer, a majority of compensated genes are generally thought to be regulated at the translational or post-translational level, and include the basic components of a compensation loop, including sensors of gene dosage and modulators of gene expression. Post-translational regulation is mostly undertaken by a general degradation or aggregation of remaining protein subunits of macromolecular complexes. An increasingly important role has also been observed for transcriptional level regulation. This article reviews the process of _targeted gene dosage compensation in cancer and other biological conditions, along with the mechanisms by which cells regulate specific genes to restore cellular homeostasis. These mechanisms represent potential _targets for the inhibition of dosage compensation of specific genes in aneuploid cancers. This article critically examines the process of _targeted gene dosage compensation in cancer and other biological contexts, alongside the criteria for identifying genes subject to dosage compensation and the intricate mechanisms by which cells orchestrate the regulation of specific genes to reinstate cellular homeostasis. Ultimately, our aim is to gain a comprehensive understanding of the intricate nature of a systems-level property. This property hinges upon the kinetic parameters of regulatory motifs, which we have termed "gene dosage sensor loops." These loops have the potential to operate at both the transcriptional and translational levels, thus emerging as promising candidates for the inhibition of dosage compensation in specific genes. Additionally, they represent novel and highly specific therapeutic _targets in the context of aneuploid cancer.
Keywords: aneuploidy; cancer; gene dosage compensation; miRNAs; systems biology.
© 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Conflict of interest statement
The authors have no relevant financial or non‐financial interests to disclose.
Figures
Similar articles
-
Extensive protein dosage compensation in aneuploid human cancers.Genome Res. 2022 Jul;32(7):1254-1270. doi: 10.1101/gr.276378.121. Epub 2022 Jun 14. Genome Res. 2022. PMID: 35701073 Free PMC article.
-
Dosage-dependent gene regulation in multicellular eukaryotes: implications for dosage compensation, aneuploid syndromes, and quantitative traits.Dev Biol. 2001 Jun 15;234(2):275-88. doi: 10.1006/dbio.2001.0262. Dev Biol. 2001. PMID: 11396999 Review.
-
Post-Translational Dosage Compensation Buffers Genetic Perturbations to Stoichiometry of Protein Complexes.PLoS Genet. 2017 Jan 25;13(1):e1006554. doi: 10.1371/journal.pgen.1006554. eCollection 2017 Jan. PLoS Genet. 2017. PMID: 28121980 Free PMC article.
-
Translational compensation of gene copy number alterations by aneuploidy in Drosophila melanogaster.Nucleic Acids Res. 2017 Apr 7;45(6):2986-2993. doi: 10.1093/nar/gkx106. Nucleic Acids Res. 2017. PMID: 28199687 Free PMC article.
-
Dosage compensation and the global re-balancing of aneuploid genomes.Genome Biol. 2010;11(8):216. doi: 10.1186/gb-2010-11-8-216. Epub 2010 Aug 26. Genome Biol. 2010. PMID: 20804581 Free PMC article. Review.
Cited by
-
Next generation sequencing technologies to address aberrant mRNA translation in cancer.NAR Cancer. 2024 May 15;6(2):zcae024. doi: 10.1093/narcan/zcae024. eCollection 2024 Jun. NAR Cancer. 2024. PMID: 38751936 Free PMC article. Review.
-
High level of aneuploidy and recurrent loss of chromosome 11 as relevant features of somatotroph pituitary tumors.J Transl Med. 2024 Nov 4;22(1):994. doi: 10.1186/s12967-024-05736-0. J Transl Med. 2024. PMID: 39497133 Free PMC article.
References
-
- Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12(1):31‐46. doi:10.1158/2159-8290.CD-21-1059 - DOI - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources